A5059289017- Psoriasis: Treatment and Pathogenesis
- Dermatology and Skin Diseases
- T-cell and B-cell Immunology
- Autoimmune Bullous Skin Diseases
- Antifungal resistance and susceptibility
- Immune Cell Function and Interaction
- Monoclonal and Polyclonal Antibodies Research
- Inflammatory Bowel Disease
- Immunotherapy and Immune Responses
- Reproductive System and Pregnancy
- Biosimilars and Bioanalytical Methods
- Asthma and respiratory diseases
- Immune Response and Inflammation
- Cutaneous lymphoproliferative disorders research
Universitat de Barcelona
2012-2022
Barcelona Biomedical Research Park
2019
Institute for Research in Biomedicine
2012
T lymphocytes expressing the CLA antigen constitute a subset of effector memory that are functionally involved in T-cell-mediated cutaneous diseases. Skin-seeking recirculate between inflamed skin and blood during inflammation. Many studies different inflammatory diseases have clearly related their pathologic mechanisms to CLA+ cells. Based on common features these cells disorders mediated by cells, we propose circulating CLA+T could very useful peripheral cellular biomarkers for
IL-15 has emerged as a potentially relevant target in the IL-17 response psoriasis. However, its mechanism is poorly characterized humans. and IL-23 are constitutively expressed psoriatic lesion. Also, considered susceptibility-associated gene psoriasis, IL-23R, HLACW6. Here, we studied effect of stimulation on cytokine CLA+/CLA- T cells from 9 psoriasis patients 3 healthy control subjects. To this end, CLA + CLA- blood samples were cultured with epidermal skin biopsies treated IL-23. After...
Candida albicans (CA) infections have been associated with psoriasis onset or disease flares. However, the integrated immune response against this fungus is still poorly characterized in psoriasis. We studied specific immunoglobulins plasma and CA cocultures of circulating memory CD45RA− cutaneous lymphocyte antigen (CLA)+/− T cell autologous epidermal cells from plaque guttate patients (cohort 1, n = 52), also healthy individuals (n 17). A complete proteomic profile was evaluated 2, 114)...
Vedolizumab is a humanized monoclonal antibody targeting the α4β7 integrin used for treatment of ulcerative colitis. Few biomarkers related to vedolizumab response have been identified. The aim this work was assess whether baseline circulating CD4+ and CD8+ memory T-lymphocyte subpopulations could help identify patients with in colitis.Prospective pilot study 15 active colitis previous failure anti-TNFα starting treatment. Peripheral blood samples were obtained before first dose at week 6 14...
Vedolizumab (VDZ) is a humanised monoclonal antibody targeting the α4β7 integrin us in ulcerative colitis (UC). So far, no biomarker of response to VDZ has been identified. To assess whether circulating CD4+ and CD8+ α4β7+/ α4β7- memory T lymphocytes are molecular markers treatment patients with UC. Prospective study, 15 active UC (Ulcerative Colitis Disease Activity Index (UCDAI) >3, Mayo endoscopic subscore >1, faecal calprotectin >250 μg/g) prior failure anti-TNFα therapy, starting ( 300...